Servier To Acquire Potential Genetic Treatment For Fragile X Syndrome For Up To $450 Million

Servier, an independent international pharmaceutical group governed by a foundation, announced that it has entered into a definitive agreement with Kaerus Bioscience for the acquisition of KER-0193, a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD). The total value of the deal could reach up to $450 million, according to the announcement. This acquisition demonstrates Servier’s commitment to building a neurology franchise by expanding its pipeline with assets targeting rare indications for consumers with high unmet need, the announcement stated.

KER-0193 was discovered and developed by Kaerus Bioscience . . .